Physician profile
Maria Alvarez
NPI 1396710539
$69,668.19
in general payments reported to CMS, 2019-2025
81 companies · $6,336 in 2025
The $6,336 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $6,655 · 2021: $6,131 · 2022: $5,653 · 2023: $5,758 · 2024: $5,963 · 2025: $6,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,809.19 |
| Education | $246.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16,259.96 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Acorda Therapeutics, INC | $14,577.40 | 2019-2024 | Inbrija, Ampyra |
| Promius Pharma LLC | $3,349.60 | 2019 | |
| Ucb, INC. | $2,902.65 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Neurocrine Biosciences, INC. | $2,824.08 | 2019-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $2,687.62 | 2019-2025 | Nuplazid |
| Abbvie INC. | $2,049.93 | 2021-2025 | Ubrelvy, Duopa, Qulipta |
| Neurelis, INC. | $1,464.28 | 2020-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $1,431.03 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Medtronic, INC. | $1,372.86 | 2021-2025 | Percept PC Brainsense, Sensight |
| Abbott Laboratories | $1,367.40 | 2019-2025 | Infinity, Proclaim, Diamondback Peripheral |
| Mdd US Operations, LLC | $1,258.99 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Lundbeck LLC | $1,107.90 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $1,105.93 | 2021-2025 | |
| Lilly USA, LLC | $1,041.97 | 2019-2025 | Amyvid, Kisunla, Emgality |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.